Please Wait...

Remote Telemonitoring

In addition to providing study participants with a home BP device, Bioclinica's remote telemonitoring solution provides a means of electronically transferring study participant, self-monitored BP data to our central repository. This allows for direct capture and upload of home BP data onto the study website.

Features of Remote Telemonitoring include:

  • Real-time access to BP data via a secure study web portal to view data and graphical results
  • Alert notifications provided based upon predetermined protocol parameters
  • Complete audit trail from data transmission in patients' homes to final analysis and submission

Benefits of Remote Telemonitoring include:

  • Access to treatment effects within the first weeks of study, which is highly predictive of longer term effects
  • Early identification of changes in BP providing enhanced safety monitoring
  • Improved patient compliance
  • Reduction in the number of office visits resulting in time and cost savings

ADDITIONAL RESOURCES

Collection and Analysis of BP data for Clinical Trials

Download WHITE PAPER

Ambulatory Blood Pressure Monitoring

Download DATA SHEET

Cardiovascular Imaging

Download DATA SHEET

Cardiac Safety Solutions

Download BROCHURE

Global Median Beat (GMB)

Download OVERVIEW SHEET

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (Yesterday)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (2 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (4 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (4 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (4 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (4 days ago)

Latest Blogs: